KRT88P, keratin 88 pseudogene, 85348

N. diseases: 24; N. variants: 0
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0019163
Disease: Hepatitis B
Hepatitis B
0.100 GeneticVariation disease BEFREE Herein, a theranostic strategy was carried to encapsulate a natural medicine (Quercetin, QR) into hepatitis B core (HBc) protein nanocages (NCs) for imaging and targeted treatment of hepatic fibrosis. 31644261 2019
CUI: C0019163
Disease: Hepatitis B
Hepatitis B
0.100 Biomarker disease BEFREE The diverse functions of the hepatitis B core/capsid protein (HBc) in the viral life cycle: Implications for the development of HBc-targeting antivirals. 29183719 2018
CUI: C0019163
Disease: Hepatitis B
Hepatitis B
0.100 AlteredExpression disease BEFREE In vitro assays with HBx, hepatitis B surface (HBs), or hepatitis B core (HBc) protein expression in HepG2 cells costimulated with ethanol were conducted to assess the cholesterol metabolism. 29133292 2018
CUI: C0019163
Disease: Hepatitis B
Hepatitis B
0.100 AlteredExpression disease BEFREE HBV-miR-3 targets the unique site of the HBV 3.5-kb transcript to specifically reduce HBc protein expression, levels of pregenomic RNA (pgRNA), and HBV replication intermediate (HBV-RI) generation but does not affect the HBV DNA polymerase level, thus suppressing HBV virion production (replication). 28148795 2017
CUI: C0019163
Disease: Hepatitis B
Hepatitis B
0.100 Biomarker disease BEFREE The prevalence of HBV infection (current or past [presence of anti-HBc marker]) was 15.4% (95% CI: 8.7-25.8) and the rate of HBsAg carriers was 0.6% (95% CI: 0.2-1.6). 27508385 2016
CUI: C0019163
Disease: Hepatitis B
Hepatitis B
0.100 Biomarker disease BEFREE We successfully inserted the 2β2-2β3 loop of PA into the major immunodominant region (MIR) of hepatitis B virus core (HBc) protein. 24054942 2014
CUI: C0019163
Disease: Hepatitis B
Hepatitis B
0.100 Biomarker disease BEFREE Capsid-like particles consisting of a hepatitis B core (HBc) protein have been studied for their potential as carriers for drug delivery systems (DDS). 23235317 2013
CUI: C0019163
Disease: Hepatitis B
Hepatitis B
0.100 GeneticVariation disease BEFREE Involvement and consequences of the proteasomal degradation machinery in the HBc protein turnover during HBV infection with complex HBV variants in the immunosuppressed patients are discussed. 17607782 2007
CUI: C0019163
Disease: Hepatitis B
Hepatitis B
0.100 AlteredExpression disease BEFREE Previous studies in rodent malaria models have shown that CS repeat B-cell epitopes expressed in a recombinant hepatitis B virus core (HBc) protein can elicit protective immunity. 12438363 2002
CUI: C0019163
Disease: Hepatitis B
Hepatitis B
0.100 Biomarker disease BEFREE Viral markers were used, including HBV DNA quantified by the branched DNA assay and detected by PCR, the HBV genome sequence, pre-S1Ag and anti-HBC IgM which were studied throughout the treatment period and the entire follow-up in the serum, while the presence of virus in extrahepatic sites was detected by immuno-staining. 11434628 2001
CUI: C0019163
Disease: Hepatitis B
Hepatitis B
0.100 Biomarker disease BEFREE We have identified the presence of a nucleotide sequence at the start of the HBc gene in the hepatitis B virus genome similar to a consensus sequence known to occur upstream from genes induced by IFN in mammalian cells. 3517227 1986
CUI: C0019163
Disease: Hepatitis B
Hepatitis B
0.100 AlteredExpression disease BEFREE The temporal relation between the cytopathologic response and HBc gene expression was similar for both cell types, indicating a primary role for HBc gene expression in the cytopathology of HBV-infected human liver. 6194563 1983
CUI: C0006142
Disease: Malignant neoplasm of breast
Malignant neoplasm of breast
0.060 Biomarker disease BEFREE Here, we aimed to identify Golgi-disrupting compounds from a panel of 34 approved anticancer drugs by using HBC-4 human breast cancer cells and immunofluorescence microscopy to visualize the Golgi apparatus. 30787205 2019
CUI: C0006142
Disease: Malignant neoplasm of breast
Malignant neoplasm of breast
0.060 GeneticVariation disease BEFREE We studied 1,018 women with a strong family history for breast cancer (families with hereditary breast cancer; HBC) from genetically homogenous population of Poland, which is populated by ethnic Slavs, for mutations in 14 cancer susceptibility genes. 31173646 2019
CUI: C0678222
Disease: Breast Carcinoma
Breast Carcinoma
0.060 GeneticVariation disease BEFREE We studied 1,018 women with a strong family history for breast cancer (families with hereditary breast cancer; HBC) from genetically homogenous population of Poland, which is populated by ethnic Slavs, for mutations in 14 cancer susceptibility genes. 31173646 2019
CUI: C0678222
Disease: Breast Carcinoma
Breast Carcinoma
0.060 Biomarker disease BEFREE Here, we aimed to identify Golgi-disrupting compounds from a panel of 34 approved anticancer drugs by using HBC-4 human breast cancer cells and immunofluorescence microscopy to visualize the Golgi apparatus. 30787205 2019
CUI: C0006142
Disease: Malignant neoplasm of breast
Malignant neoplasm of breast
0.060 Biomarker disease BEFREE HBC-Evo: predicting human breast cancer by exploiting amino acid sequence-based feature spaces and evolutionary ensemble system. 25488423 2015
CUI: C0678222
Disease: Breast Carcinoma
Breast Carcinoma
0.060 Biomarker disease BEFREE HBC-Evo: predicting human breast cancer by exploiting amino acid sequence-based feature spaces and evolutionary ensemble system. 25488423 2015
CUI: C0006142
Disease: Malignant neoplasm of breast
Malignant neoplasm of breast
0.060 Biomarker disease BEFREE In spite of the recent demonstration and chromosomal localization of BC predisposing genes, clinical clues and careful inspection of pedigree still remain major instruments in HBC diagnosis. 10517166 1999
CUI: C0678222
Disease: Breast Carcinoma
Breast Carcinoma
0.060 Biomarker disease BEFREE In spite of the recent demonstration and chromosomal localization of BC predisposing genes, clinical clues and careful inspection of pedigree still remain major instruments in HBC diagnosis. 10517166 1999
CUI: C0006142
Disease: Malignant neoplasm of breast
Malignant neoplasm of breast
0.060 Biomarker disease BEFREE Two hypermethylation-containing fragments, HBC-1 (for "hypermethylation in breast cancer") and HBC-2, were identified in the amplified breast tumor DNA relative to the amplified normal breast DNA of a patient. 9067264 1997
CUI: C0678222
Disease: Breast Carcinoma
Breast Carcinoma
0.060 Biomarker disease BEFREE Further analysis showed that HBC-1 was methylated aberrantly in 90% (17 of 19 patients) of the primary breast carcinomas examined. 9067264 1997
CUI: C0006142
Disease: Malignant neoplasm of breast
Malignant neoplasm of breast
0.060 Biomarker disease BEFREE HBC is common, accounting for approximately 9% of the total breast cancer burden. 2692910 1989
CUI: C0678222
Disease: Breast Carcinoma
Breast Carcinoma
0.060 Biomarker disease BEFREE HBC is common, accounting for approximately 9% of the total breast cancer burden. 2692910 1989
Hereditary Breast and Ovarian Cancer Syndrome
0.020 GeneticVariation disease BEFREE Specific germline mutations in the hereditary breast-ovarian cancer susceptibility (HBC/HBOC) genes, BRCA1, BRCA2 and PALB2, have been shown to recur in French Canadians of Quebec, Canada, and this has been attributed to common ancestors. 25925845 2015